13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • CINN

    Acronym: 

    CINN

    ACTRN/NCT /ethics: 

    Scientific title: 

    Summary of trial and patient characteristics

    Cancer Type Lung & mesothelioma
    Trial Type Treatment
    Phase Phase II Tumour Stream NSLC
    Age Range 18 years and older Cancer Stage Metastatic or Widespread, Locally Recurrent or Locally Advanced
    Sex Both Anticipated Start Date
    Molecular Target Anticipated End Date
    Cancer Type Lung & mesothelioma
    Trial Type Treatment
    Phase Phase II
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream NSLC
    Cancer Stage Metastatic or Widespread, Locally Recurrent or Locally Advanced
    Anticipated Start Date
    Anticipated End Date

    Trial Summary

    A randomized, open label, multicenter phase II study evaluating the efficacy and safety of Capmatinib (INC280) plus Pembrolizumab versus Pembrolizumab alone as first line treatment for locally advanced or metastatic non-small cell lung cancer with PD-L1? 50%

    Lay Summary

    Sponsor / Cooperative group

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Calvary North Adelaide Hospital Julie Rowe julie.rowe@calvarycare.org.au 08 8239 9536 Not Yet Recruiting